Regulation & Government Intervention

  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon
 

Let Micro Mobility Move

The economic growth brought by legalization will bring 17.8 billion NIS over the next five years 

Private and Public Hospitals

Strengthening private health care within the public system increases the ability of public hospitals to retain senior physicians and balanced budgets.

The Sport Law

Israeli Sports Law and other regulations put in place by the Culture and Sports Ministry form an obstacle to participation in sport, especially among children

 

U.S Military 

Aid to Israel

“Economic and Strategic Ramifications of American Assistance to Israel” argues that foreign aid is actually harming the State of Israel. In 1973 Israel began to receive massive amounts of subsidies from the US. As a result, Israeli politicians lost the incentive to fix deficits and otherwise put Israel’s economic house in order.

Small Farms

in the Negev

This paper examines the economic and environmental benefits accruing from small homesteads in the Negev and urges the government to resolve specific legal and zoning issues preventing their future development.

Building New 

Communities

Israeli land policy is centralized the State owns 93 percent of the land. In recent years bureaucracy made it difficult to establish new townships in Israel's periphery (the Negev and Galilee).

U.S Military 

Aid to Israel

“Economic and Strategic Ramifications of American Assistance to Israel” argues that foreign aid is actually harming the State of Israel. In 1973 Israel began to receive massive amounts of subsidies from the US. As a result, Israeli politicians lost the incentive to fix deficits and otherwise put Israel’s economic house in order.

The Future of Public Television

This paper shows that in 2009, the public paid 425 NIS million in television fees, although at peak times, the public television channel receives less than 5 % viewing .

Reducing Barriers to Development

This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process.